UBS Downgrades Amgen On 'Waiting Game,' Removes Brodalumab From Model
July 09, 2015 at 08:15 AM EDT
In a report published Thursday, UBS analyst Matthew Roden downgraded the rating on Amgen, Inc. (NASDAQ: AMGN) from Buy to Neutral, while ...
